Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805–16—Following a routine internal audit, the findings in this Article have been slightly updated. In the main paper, this has affected only the incidence of ischaemic heart disease (Summary Findings; last paragraph of Results; table 2), mortality from causes other than breast cancer (Summary Findings), and, also in table 2, mortality among women with unknown ER status (and hence among women with any ER status). No event rate ratio has been changed by more than 0·01. The main paper and appendix have been updated online as of April 27, 2017.
. 2017 May 13;389(10082):1884. doi: 10.1016/S0140-6736(17)31004-8